Updated Apr 09, 2020
Improve (in silico or others) methods to identify compounds with blocking interactions relevant to any SARS-CoV-2 target, by optimizing/accelerating the use of HPC (High Performance Computing) or Artificial Intelligence, and providing experimental validation.
The GrandChallenge will proceed in three stages, where stage 1 and 2 are sequential and stage 3 runs in parallel. The aim is to get high quality lead compounds for multiple Covid-19 targets by cross-checking multiple simulation approaches. The top scoring compounds will be analyzed experimentally using direct affinity assays, structural analysis, as well as cell-based and in vivo viral assays. A special prize will be awarded for reduction of the yield of infectious virus by > 99% in cell culture using already FDA-approved drugs/compounds at sub-micromolar concentrations, and proven effectiveness in an animal model at physiologically relevant doses.
|Region||Africa, Asia and Pacific, Europe and Eurasia, Latin America / Caribbean, North America, Middle East and North Africa and Low and Middle Income Countries|
|Focus Areas||Infectious & Vector Diseases (Health)|
Response Technologies (Humanitarian Assistance)
This challenge is open to any team in the world and requires breakthrough approaches in computational methods and collaboration of teams ranging from computation, compound synthesis, drug development, virology, and clinical models.
Applications can be submitted online starting April 14, 2020.